LITTLE KNOWN FACTS ABOUT LEAP-2.

In the multiday, multiple-dose arm, baseline microbiota was similar amongst topics that acquired ibezapolstat in comparison with vancomycin. At Working day ten of dosing, differential abundance Investigation and β-diversity demonstrated a distinct distinction between the microbiome in topics presented vancomycin compared with either dose of ibezap